Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination With Pembrolizumab Versus Investigator's Choice in HLA-A*02:01-positive Participants With Previously Treated Advanced Melanoma (TEBE-AM)

Trial Profile

Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination With Pembrolizumab Versus Investigator's Choice in HLA-A*02:01-positive Participants With Previously Treated Advanced Melanoma (TEBE-AM)

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 14 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; Tebentafusp (Primary)
  • Indications Malignant melanoma; Skin cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms TEBE-AM
  • Sponsors Immunocore

Most Recent Events

  • 07 May 2025 According to an Immunocore media release, company is on track for Phase 3 TEBE-AM trial to complete enrollment in 1H 2026.
  • 10 Jan 2025 According to an Immunocore media release, potential data readouts expected in 2026.
  • 02 Dec 2024 Planned number of patients changed from 460 to 540.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top